Propranolol disposition after acute myocardial infarction

Area of Science:

• Pharmacology
• Cardiology
• Clinical Pharmacokinetics

Background:

• Propranolol is a beta-blocker used in cardiovascular conditions.
• Understanding its pharmacokinetics in myocardial infarction (MI) is crucial for effective treatment.
• Interindividual variability in drug concentration necessitates careful dosing.

Purpose of the Study:

• To investigate serum propranolol concentration, elimination half-life (t 1/2), and protein binding in patients with MI compared to those with chest pain (CP).
• To assess the impact of MI on propranolol's pharmacokinetic profile.
• To inform potential therapeutic regimen adjustments.

Main Methods:

• A combined intravenous/oral propranolol regimen was administered to 20 MI patients and 15 CP patients.
• Serum propranolol concentrations, elimination t 1/2, and protein binding were measured.
• Alpha-1-acid glycoprotein levels and hemodynamic parameters were also assessed.

Main Results:

• Significant interindividual variation in propranolol concentrations (1000%) was observed in both groups.
• MI patients exhibited a concentration trough at 7 hours, absent in CP patients.
• Higher alpha-1-acid glycoprotein and reduced unbound propranolol were noted 27 hours post-MI, leading to lower free propranolol concentrations at 7 and 11 hours in the MI group.

Conclusions:

• Propranolol pharmacokinetics are altered in patients following myocardial infarction.
• The observed changes, particularly in protein binding and free drug concentrations, suggest a need for modified dosing strategies.
• Increased initial propranolol dosage may improve therapeutic outcomes in MI patients.